Navigation Links
UC San Diego Superfund Research Program receives $15 million grant renewal

The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, has renewed funding for the Superfund Research Program (SRP) at the University of California, San Diego. Over the next five years, the $15 million grant will fund continued research on the molecular and genetic consequences of exposure to uncontrolled toxicants from Superfund and other hazardous waste sites.

It is the third funding cycle for UC San Diego's SRP, which was originally funded by the NIEHS in 2000.

"The overall goal of the Superfund Research Program is to understand why environmental toxicants cause disease," said Robert H. Tukey, PhD, Professor of Pharmacology, Chemistry & Biochemistry at UC San Diego and Director of the UC San Diego SRP. "Our focus is on the development of novel biological models to define how toxicant exposure leads to illness and disease. We want to learn how to better detect toxicants and model the health effects of exposure, assess the risks, and find effective ways to remediate."

Since 2000, the SRP at UC San Diego has chalked some notable achievements. Most recently:

  • Michael Karin, PhD, Distinguished Professor of Pharmacology in UC San Diego's Laboratory of Gene Regulation and Signal Transduction, has identified initiating cells in the liver that progress into liver cancer following exposure to chemical carcinogens. The identity of these cells may lead to an understanding of the mechanisms that underlie the development of liver cancer.
  • Robert Tukey, PhD has produced new mouse models expressing human genes that result in dramatically elevated levels of serum bilirubin, a potent and natural antioxidant that can be used to study the role of oxidative stress in toxicant-induced disease.
  • Julian Schroeder, PhD, in the Biology Department at UC San Diego, has used the plant model Arabidopsis to create genetically engineered plants that may eventually prove useful to bioaccumulate heavy metals from contaminated soils on a commercially viable scale.
  • David Brenner, MD, vice chancellor of UC San Diego Health Sciences, and Dean of the UCSD School of Medicine, and Ekihiro Seki, MD, from the Department of Medicine, have investigated the genetic mechanisms that lead to the development of toxicant induced liver fibrosis.
  • Ronald Evans, PhD, at the Salk Institute, has identified key cellular receptors that serve to transport environmental toxicants to the nucleus, allowing for identification of the genes that may lead to disease.
  • Paul Russell, PhD, at the Scripps Research Institute, has been successful in using yeast to characterize intracellular proteins important in arsenic induced toxicity.
  • William Trogler, PhD, Professor of Chemistry and Biochemistry, has developed novel chemical tools to detect toxicant exposure in the environment.

On-going and future projects, said Tukey, will use functional genomics and proteomics to investigate the cellular and molecular responses leading to toxicant -induced liver toxicity.

The SRP at UC San Diego is broad-based, with biomedical researchers, chemists, plant biologists, and public outreach experts. It includes research projects led by scientists from other institutions, including The Scripps Research Institute, the Salk Institute for Biological Studies and the Howard Hughes Medical Institute.

Contact: Scott LaFee
University of California - San Diego

Related medicine news :

1. UC San Diego among first in nation to treat brain cancer with novel viral vector
2. UC San Diegos William C. Mobley recognized for contributions to Down syndrome
3. AAAS Pacific Division to convene joint session with world mummy scholars in San Diego
4. Study finds Filipino children in San Diego County at higher risk for Kawasaki disease
5. UC San Diego receives 2 major biomedical informatics grants
6. UC San Diego researchers identify factor boosting leukemias aggressiveness
7. La Jolla Institute to develop San Diegos first center for RNAi genomics research
8. UC San Diego partners with Mozambique University to deliver quality health care
9. UC San Diego researcher awarded $3.8 million for new path to breast cancer therapy
10. Type 1 diabetes research at UC San Diego gets $5 million boost
11. UC San Diegos Karin receives prestigious Harvey Prize
Post Your Comments:
Related Image:
UC San Diego Superfund Research Program receives $15 million grant renewal
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: